Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion

  • Retinal Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the prognostic factors for visual outcome after intravitreal bevacizumab injection to treat macular edema due to branch retinal vein occlusion (BRVO).

Methods

Fifty eyes of 50 consecutive patients treated with intravitreal bevacizumab for macular edema due to BRVO with minimum follow-up of 3 months were retrospectively reviewed. Patients were categorized into two groups according to the final visual acuity. Group 1 consisted of eyes with 5 or more ETDRS letters gain, and group 2 consisted of eyes with less than 5 letters improvement or which had worsened at last follow-up visit. Comparative clinical and fluorescein angiographic characteristics were analyzed between the two groups.

Results

Of 50 eyes, 28 (56%) had improved vision after intravitreal bevacizumab injections and were categorized as group 1; 22 eyes (44%) were categorized as group 2. The number of early VA gainers, who showed visual improvement at 1 month after bevacizumab injection, was significantly higher in group 1 (P < 0.001, chi-square test). The early gainers tend to maintain significantly better visual outcome until last follow-up. The number of eyes with angiographically documented macular ischemia was significantly higher in group 2 (P < 0.001). In group 2, the decrease in central macular thickness was not accompanied by visual acuity improvement.

Conclusion

Preoperative presence of macular ischemia can be useful in predicting the outcome of visual acuity after intravitreal bevacizumab for macular edema due to BRVO. The early gainers who favorably responded to the initial intravitreal bevacizumab injection are most likely to benefit from the bevacizumab treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247

    PubMed  CAS  Google Scholar 

  2. The Branch Vein Occlusion Study Group (1984) Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98:271–282

    Google Scholar 

  3. Greer DV, Constable IJ, Cooper RL (1980) Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 8:207–209

    Article  PubMed  CAS  Google Scholar 

  4. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611

    Article  PubMed  CAS  Google Scholar 

  5. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP (2003) VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44:2155–2162

    Article  PubMed  Google Scholar 

  6. Funatsu H, Yamashita H, Noma H, Mimura T, Nakamura S, Sakata K, Hori S (2005) Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol 243:3–8

    Article  PubMed  CAS  Google Scholar 

  7. Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141–149

    Article  PubMed  Google Scholar 

  8. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284

    Article  PubMed  Google Scholar 

  9. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

    Article  PubMed  Google Scholar 

  10. Mulcahy MF, Benson AB 3rd (2005) Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 5:997–1005

    Article  PubMed  CAS  Google Scholar 

  11. Mason JO 3rd, Albert MA Jr, Mays A, Vail R (2006) Regression of neovascular iris vessels by intravitreal injection of bevacizumab. Retina 26:839–841

    Article  PubMed  Google Scholar 

  12. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999–1005

    Article  PubMed  Google Scholar 

  13. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743–750

    Article  PubMed  Google Scholar 

  14. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606

    Article  PubMed  CAS  Google Scholar 

  15. Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425

    Article  PubMed  Google Scholar 

  16. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339

    PubMed  Google Scholar 

  17. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I (1982) New visual acuity charts for clinical research. Am J Ophthalmol 94:91–96

    PubMed  Google Scholar 

  18. Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger SG (2008) Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92:351–355

    Article  PubMed  CAS  Google Scholar 

  19. Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular edema secondary to retinal vein occlusion - a prospective study. Br J Ophthalmol 92:518–522

    Article  PubMed  CAS  Google Scholar 

  20. Shilling JS, Jones CA (1984) Retinal branch vein occlusion: a study of argon laser photocoagulation in the treatment of macular oedema. Br J Ophthalmol 68:196–198

    Article  PubMed  CAS  Google Scholar 

  21. Chen SD, Sundaram V, Lochhead J, Patel CK (2006) Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 141:876–883

    Article  PubMed  CAS  Google Scholar 

  22. Gutman FA, Zegarra H (1974) The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 78:OP178–OP192

    PubMed  CAS  Google Scholar 

  23. Beer PM, Wong SJ, Hammad AM, Falk NS, O’Malley KS (2006) Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. Retina 26:871–876

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, NHIC Ilsan Hospital, Gyounggi-do, Korea

    Eun Jee Chung

  2. The Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea

    Eun Jee Chung, Young Taek Hong, Sung Chul Lee, Oh Woong Kwon & Hyoung Jun Koh

  3. Department of Ophthalmology, Yonsei University College of Medicine, Sodaemungu Shinchondong 134, Seoul, 120-752, Korea

    Hyoung Jun Koh

Authors
  1. Eun Jee Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Young Taek Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sung Chul Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oh Woong Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hyoung Jun Koh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyoung Jun Koh.

Additional information

The authors have no proprietary or financial interest in any of the products used in this study.

Presented in part at World Ophthalmology Congress, June 2008, Hong Kong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chung, E.J., Hong, Y.T., Lee, S.C. et al. Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246, 1241–1247 (2008). https://doi.org/10.1007/s00417-008-0866-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-008-0866-8

Keywords

Search

Navigation